Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Leases: 2020-2024

Historic Current Leases for Altimmune (ALT) over the last 5 years, with Dec 2024 value amounting to $279,000.

  • Altimmune's Current Leases fell 21.09% to $247,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $247,000, marking a year-over-year decrease of 21.09%. This contributed to the annual value of $279,000 for FY2024, which is 43.75% down from last year.
  • According to the latest figures from FY2024, Altimmune's Current Leases is $279,000, which was down 43.75% from $496,000 recorded in FY2023.
  • In the past 5 years, Altimmune's Current Leases registered a high of $496,000 during FY2023, and its lowest value of $279,000 during FY2024.
  • For the 3-year period, Altimmune's Current Leases averaged around $409,000, with its median value being $452,000 (2022).
  • As far as peak fluctuations go, Altimmune's Current Leases grew by 15.22% in 2021, and later plummeted by 43.75% in 2024.
  • Altimmune's Current Leases (Yearly) stood at $356,716 in 2020, then increased by 15.22% to $411,000 in 2021, then increased by 9.98% to $452,000 in 2022, then rose by 9.73% to $496,000 in 2023, then slumped by 43.75% to $279,000 in 2024.